

July 19, 2017



# Sucampo Announces Second Quarter 2017 Earnings Call

ROCKVILLE, Md., July 19, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its second quarter 2017 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, August 2nd. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.

Individuals interested in accessing the live audio webcast of the teleconference may do so at <http://www.sucampo.com/investors/events-presentations/> and should log on 10 to 15 minutes before the teleconference begins to download any software required.

Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo's website for several days after the live event. Alternatively, individuals may dial 888-636-8238 (domestic) or 484-747-6635 (international) and use passcode 53377840. A replay of the teleconference will be available by dialing 855-859-2056 (domestic) or 404-537-3406 (international), passcode 53377840, approximately two hours after the teleconference concludes. The archive of the teleconference will be available for 30 days.

## About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a 2-hydroxypropyl-beta-cyclodextrin product with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 also has been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP1-x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit [www.sucampo.com](http://www.sucampo.com).

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Follow us on Twitter (@Sucampo\_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

[Twitter](#) [LinkedIn](#)

Contact:

Sucampo Pharmaceuticals, Inc.

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

1-240-223-3718

staylor@sucampo.com



Source: Sucampo Pharmaceuticals Inc